News and Releases | EyegatePharma.com

EyeGate Announces Positive Top-line Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Post-Operative Inflammation and Pain in Cataract Surgery Patients

WALTHAM, Mass., Aug. 01, 2016 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced positive data from its Phase 1b/2a trial assessing its lead product candidate, iontophoretic EGP-437, in the treatment of post-operative ocular…

July 3, 2023adminPress Releases

EyeGate Announces Randomization of First Patients in Study for Punctate Epitheliopathies

WALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that the first three patients have been randomized in its study evaluating the ability of EyeGate’s Ocular Bandage Gel (OBG) to reduce…

July 3, 2023adminPress Releases

EyeGate Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract Surgery

EGP-437 demonstrated better clinical performance than vehicle control but did not meet its co-primary endpoints WALTHAM, Mass., Feb. 05, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced top-line results from a Phase 2b…

July 3, 2023adminPress Releases

EyeGate Announces $11.25 Million Public Offering

WALTHAM, Mass., April 13, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, announced today the pricing of a public offering of an aggregate of 35,156,250 shares of common stock (or common stock equivalents) and warrants…

July 3, 2023adminPress Releases

EyeGate Announces $3.77 Million Registered Direct Offering

WALTHAM, Mass., June 27, 2016 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that it has entered into a definitive agreement with a single healthcare dedicated institutional investor to purchase shares…

July 3, 2023adminPress Releases

EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

WALTHAM, MA, December 31, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, today announced that it has entered into a definitive agreement with certain institutional investors to purchase 500,000 shares of the Company’s common stock at a purchase…

July 3, 2023adminPress Releases

EyeGate Announces Completion of $11.25 Million Public Offering

WALTHAM, Mass., April 17, 2018 — EyeGate Pharmaceuticals, Inc. (Nasdaq:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, announced today the completion of its previously announced public offering of 14,730,000 shares of the Company’s common stock, 6,536.4 shares of Series…

July 3, 2023adminPress Releases

EyeGate Announces Completion of $3.77 Million Registered Direct Offering

WALTHAM, Mass., June 30, 2016 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced the completion of its previously announced offering of the Company’s common stock and of Series A Convertible…

July 3, 2023adminPress Releases

EyeGate Announces Completion of $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

WALTHAM, MA, January 3, 2020 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, today announced the completion of its previously announced registered direct offering priced at-the-market under Nasdaq Rules of 500,000 shares of the Company’s common stock at a…

July 3, 2023adminPress Releases

EyeGate Announces Encouraging Interim Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Ocular Inflammation and Pain Post Cataract Surgery

WALTHAM, Mass., June 01, 2016 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced interim data from its Phase 1b/2a trial evaluating its lead product candidate, iontophoretic EGP-437, in the treatment of…

July 3, 2023adminPress Releases

Category: News and Releases